This month we have selected the guidelines dedicated to the invasive therapeutic pathways for Parkinson's disease, published jointly by the EAN and the Movement Disorder Society-European Section.

Our paper of the month for October investigates vestibular function in patients with dizziness, vertigo and postural symptoms following COVID-19 vaccination.

Read the latest reports from EAN Clinical Fellowship participants on their experiences in London and Bologna.

Trick or Treat? For the month of October, we are clearly handing out the goodies, with new cases Dementia and Movement Disorders, as well as several webcasts and guidelines now freely available for all with a myEAN account.

With relatively few chances for EAN staff and members to meet in person, we decided to use this platform to present the team behind the scenes. This time it's Gottfried, our Head of IT, and Sylwia from the Congress Department.

The application deadline for next year's EAN Clinical Fellowships - 31 October 2022 - is fast approaching!

Our pick of Covid-related cross-sectional case control studies from the scientific press for October 2022

Read on for our highlighted selection of Covid-related Literature Reviews from the scientific press for October 2022.

Our highlighted selection of recent Covid-related case series or case reports from the scientific press for October 2022.

The 2017 McDonald criteria showed higher sensitivity, lower specificity, and similar accuracy in predicting clinically definite multiple sclerosis compared to 2010 McDonald criteria, while shortening time to its diagnosis.

Insidious disability accrual starts already in the earliest phases of multiple sclerosis and becomes dominant over the disease course, suggesting an ongoing process of inflammation and/or degeneration secondary to disease burden.

Epstein-Barr virus infection is the strongest known risk factor for the development of multiple sclerosis, and it precedes preclinical manifestation of the disease suggesting a possible causal role

In multiple sclerosis, an impairment of the glymphatic system may contribute to pathology accrual in the central nervous system and disability progression.

Baseline characteristics of Aβ-positive individuals can help identify those who will remain tau-negative for at least 5 years.

Greater diffusion restriction in the white matter of amyloid-beta-positive cognitively unimpaired individuals supports the role of inflammation in early preclinical AD.